Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report

Shigehisa Kubota; Susumu Kageyama; Masayuki Nagasawa; Akinori Wada; Ryo Ikari; Keiji Tomita; Tetsuya Yoshida; Mitsuhiro Narita; Akihiro Kawauchi

doi:10.12659/AJCR.930989

05 July 2021 : Case report Japan

Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report

Unusual clinical course, Unusual or unexpected effect of treatment

Shigehisa Kubota^1ABCDEF, Susumu Kageyama^1ADE*, Masayuki Nagasawa^1CF, Akinori Wada^1BC, Ryo Ikari^1BD, Keiji Tomita^1DF, Tetsuya Yoshida^1ABF, Mitsuhiro Narita^1ADF, Akihiro Kawauchi^1ADE

DOI: 10.12659/AJCR.930989

Am J Case Rep 2021; 22:e930989

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 2. Clinical course after initiation of cabazitaxel chemotherapy. LH-RH – luteinizing hormone-releasing hormone; CBZ – cabazitaxel; PSA – prostate-specific antigen.

Back to the Article

Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report

Your Privacy